1. Scrip
  2. >>Business
  3. >>Financing

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

 
• By Mandy Jackson

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

Venture Capital Concept on the Mechanism of Metal Gears.
venBio raised $394m for its third fund; its prior fund totaled $340m • Source: Shutterstock

Economic uncertainty tied to the ongoing COVID-19 pandemic did not keep the life science-focused venture capital firm venBio from being able to close its third fund, which totaled $394m. In fact, the fund was oversubscribed, surpassing venBio’s initial goal of $250m, with heavy interest from big pharma companies and other investors, according to managing partner Corey Goodman.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

 
• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.

Trump’s Tariffs Add To European Warning Of $100bn US Exodus

 
• By Andrew McConaghie

European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.

Will Irish Eyes Still Be Smiling When Trump Tariffs Hits Pharma?

 
• By Kevin Grogan

The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.